An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice.

BACKGROUND & AIMS Drugs used to treat patients with ulcerative colitis are not always effective because of nonspecific distribution, metabolism in the gastrointestinal tract, and side effects. We designed a nitroxide radical-containing nanoparticle (RNP(O)) that accumulates specifically in the colon to suppress inflammation and reduce the undesirable side effects of nitroxide radicals. METHODS RNP(O) was synthesized by assembly of an amphiphilic block copolymer that contains stable nitroxide radicals in an ether-linked hydrophobic side chain. Biodistribution of RNP(O) in mice was determined from radioisotope and electron spin resonance measurements. The effects of RNP(O) were determined in mice with dextran sodium sulfate (DSS)-induced colitis and compared with those of low-molecular-weight drugs (4-hydroxyl-2,2,6,6-tetramethylpiperidine-1-oxyl [TEMPOL] or mesalamine). RESULTS RNP(O), with a diameter of 40 nm and a shell of poly(ethylene glycol), had a significantly greater level of accumulation in the colonic mucosa than low-molecular-weight TEMPOL or polystyrene latex particles. RNP(O) was not absorbed into the bloodstream through the intestinal wall, despite its long-term retention in the colon, which prevented its distribution to other parts of the body. Mice with DSS-induced colitis had significantly lower disease activity index and less inflammation following 7 days of oral administration of RNP(O) compared with mice with DSS-induced colitis or mice given low-molecular-weight TEMPOL or mesalamine. CONCLUSIONS We designed an orally administered RNP(O) that accumulates specifically in the colons of mice with colitis and is more effective in reducing inflammation than low-molecular-weight TEMPOL or mesalamine. RNP(O) might be developed for treatment of patients with ulcerative colitis.

[1]  M. Nagarkatti,et al.  American ginseng suppresses inflammation and DNA damage associated with mouse colitis , 2008, Carcinogenesis.

[2]  B. Aggarwal,et al.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. , 2009, The international journal of biochemistry & cell biology.

[3]  D. Podolsky,et al.  Inflammatory bowel disease. , 2002, The New England journal of medicine.

[4]  Akira Matsumura,et al.  Newly Synthesized Radical-Containing Nanoparticles Enhance Neuroprotection After Cerebral Ischemia-Reperfusion Injury , 2011, Neurosurgery.

[5]  Y. Nagasaki,et al.  The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles. , 2011, Biomaterials.

[6]  D. Rampton,et al.  Inflammatory bowel disease--a radical view. , 1993, Gut.

[7]  Gang Lu,et al.  A γ-Tocopherol–Rich Mixture of Tocopherols Inhibits Colon Inflammation and Carcinogenesis in Azoxymethane and Dextran Sulfate Sodium–Treated Mice , 2009, Cancer Prevention Research.

[8]  B. Harmon,et al.  A flow cytometric study of cell death: Failure of some models to correlate with morphological assessment , 1994, Immunology and cell biology.

[9]  J. McCord,et al.  The evolution of free radicals and oxidative stress. , 2000, The American journal of medicine.

[10]  D. Pompliano,et al.  Nat. Rev. Drug Disc. , 2007 .

[11]  K. Toh,et al.  Chemical nanotherapy: nitroxyl radical-containing nanoparticle protects neuroblastoma SH-SY5Y cells from Abeta-induced oxidative stress. , 2011, Therapeutic delivery.

[12]  Kazunori Kataoka,et al.  PEGylated Nanoparticles for Biological and Pharmaceutical Applications , 2003 .

[13]  Soriano,et al.  The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. , 2000, Colloids and surfaces. B, Biointerfaces.

[14]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[15]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[16]  Claus-Michael Lehr,et al.  Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa , 2001, Pharmaceutical Research.

[17]  Y. Nagasaki,et al.  Nitroxyl radical-containing nanoparticles for novel nanomedicine against oxidative stress injury. , 2011, Nanomedicine.

[18]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[19]  Jun Fang,et al.  Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. , 2003, International immunopharmacology.

[20]  Y. Nagasaki,et al.  Design of core--shell-type nanoparticles carrying stable radicals in the core. , 2009, Biomacromolecules.

[21]  J. Hanes,et al.  Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. , 2009, Advanced drug delivery reviews.

[22]  S. Hanauer.  Medical therapy for ulcerative colitis 2004. , 2004, Gastroenterology.

[23]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[24]  D. Friend.  New oral delivery systems for treatment of inflammatory bowel disease. , 2005, Advanced drug delivery reviews.

[25]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[26]  M. Cristea,et al.  Polymeric micelles for oral drug delivery: Why and how , 2004 .

[27]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[28]  R. Xavier,et al.  Genetics and pathogenesis of inflammatory bowel disease , 2011, Nature.

[29]  H. Matsui,et al.  pH-sensitive radical-containing-nanoparticle (RNP) for the L-band-EPR imaging of low pH circumstances. , 2009, Bioconjugate chemistry.

[30]  E. Loftus.  Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. , 2004, Gastroenterology.

[31]  M. Regueiro,et al.  Medical therapy for ulcerative colitis. , 2002, Gastroenterology clinics of North America.

[32]  Melinda Fitzgerald,et al.  Immunol. Cell Biol. , 1995 .

[33]  Judy H Cho,et al.  Inflammatory bowel disease. , 2009, The New England journal of medicine.

[34]  G. Dalmasso,et al.  Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. , 2010, Gastroenterology.

[35]  Lori A. Coburn,et al.  The Apolipoprotein E-Mimetic Peptide COG112 Inhibits NF-κB Signaling, Proinflammatory Cytokine Expression, and Disease Activity in Murine Models of Colitis* , 2010, The Journal of Biological Chemistry.

[36]  C. Babbs.  Oxygen radicals in ulcerative colitis. , 1992, Free radical biology & medicine.

[37]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[38]  C. McClain,et al.  Antioxidants as novel therapy in a murine model of colitis. , 2005, The Journal of nutritional biochemistry.

[39]  R. Newcombe,et al.  Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. , 1994, Gut.

[40]  I. Larre,et al.  New diseases derived or associated with the tight junction. , 2007, Archives of medical research.

[41]  R. Xavier,et al.  Unravelling the pathogenesis of inflammatory bowel disease , 2007, Nature.

[42]  T. Sawada,et al.  [Medical therapy in ulcerative colitis]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.

[43]  H. Isoda,et al.  The use of nitroxide radical-containing nanoparticles coupled with piperine to protect neuroblastoma SH-SY5Y cells from Aβ-induced oxidative stress. , 2011, Biomaterials.

[44]  D. Teitelbaum,et al.  Colostomy: formation and closure , 2006 .